T cell and B cell activation pathways

T cell and B cell activation pathways represent the fundamental signaling networks that drive the adaptive immune response. T cell activation typically requires two signals: the recognition of an antigen-MHC complex by the T cell receptor (TCR) and a co-stimulatory signal, most commonly through CD28 (Janeway's Immunobiology, 2016). B cell activation occurs via the B cell receptor (BCR) and is often enhanced by T cell help through CD40-CD40L interactions (Nature Reviews Immunology, 2021). These pathways trigger downstream signaling through kinases like Lck, ZAP-70, and Syk, leading to the activation of transcription factors such as NFAT, NF-κB, and AP-1. Dysregulation of these pathways is a hallmark of autoimmune diseases, where the immune system attacks self-tissues, and in cancer, where pathways may be suppressed to evade immune detection (StatPearls, 2023). Consequently, these pathways are major therapeutic targets for a wide variety of clinical indications. Drugs like cyclosporine and tacrolimus inhibit T cell activation to prevent organ transplant rejection by targeting the calcineurin pathway. Conversely, checkpoint inhibitors like pembrolizumab reactivate T cells to treat various cancers by blocking inhibitory signals (NIH, 2024). B cell-targeted therapies, such as rituximab, deplete B cells to treat lymphomas and autoimmune conditions. Overall, modulating these pathways allows for precise control over immune-mediated pathology and therapeutic enhancement of anti-tumor activity.

Other names

Lymphocyte activation pathwaysAdaptive immune signalingT-cell and B-cell signaling cascades

Modulation of intracellular signaling cascades (e.g., calcineurin or mTOR inhibition), blockade of co-stimulatory or inhibitory checkpoint receptors, and depletion of specific lymphocyte populations to regulate immune activity.